Investors tracking the health insurance sector have increasingly turned their attention to two technology-enabled insurers: Clover Health Investments (CLOV) and Oscar Health (OSCR). Both companies pair insurance products with proprietary software platforms, yet they serve distinct customer bases and are at different stages of financial maturity. A stock comparison between the two is particularly relevant for growth-oriented traders and investors evaluating relative performance, market positioning, and the durability of recent momentum. Understanding how CLOV and OSCR differ in business model, catalysts, and risk profile can help clarify which name better fits current market conditions. I also checked this using Tickeron’s AI Screener to see how the stocks compare to others in the industry.
Clover Health Investments is a physician-enablement technology company that offers Medicare Advantage plans to seniors, powered by its Clover Assistant software platform, which aggregates patient data to support clinical decision-making. In recent weeks, CLOV has reported accelerating revenue and membership growth. For the third quarter, revenue rose roughly 53% year over year, and average Medicare Advantage membership grew about 46%, reaching approximately 159,000 members. Management has signaled confidence in delivering the company's first full year of GAAP net income profitability in 2026, supported by improving cohort economics, operating leverage, and a five-star rating on its flagship PPO plan for Payment Year 2028. The stock has shown notable volatility, and while momentum has strengthened, CLOV remains a smaller-capitalization name with a more concentrated geographic footprint, primarily in New Jersey and Georgia.
Oscar Health is a technology-driven health insurer built on a full-stack platform, with its core business in the ACA individual and family insurance market, alongside products such as ICHRA solutions and its Lucie Health Marketplace. In recent market activity, OSCR has reported exceptional top-line growth, with third-quarter revenue rising about 72% year over year to approximately $5.1 billion, driven by premium rate increases, membership gains, and a favorable risk-adjustment adjustment. The company swung to a quarterly net profit, improved its medical loss ratio to 84%, and raised its full-year earnings outlook for the third time in 2026. With a footprint spanning more than 20 states and a much larger membership base, OSCR has drawn broad investor interest, though its profitability has been partly supported by one-time accounting benefits that warrant scrutiny. From what I see, this kind of consistent execution stands out.
The clearest contrast between the two companies is their market focus and scale. CLOV is concentrated in Medicare Advantage, a government-regulated senior market where its Clover Assistant platform and five-star quality ratings represent key competitive advantages, but where regulatory and geographic concentration present meaningful risks. OSCR operates in the ACA individual market, which is broader but highly sensitive to policy decisions such as premium tax credits and enrollment rules. In terms of growth drivers, CLOV is compounding membership and revenue more rapidly from a smaller base, while OSCR is scaling a much larger book and expanding its geographic footprint. On profitability, OSCR is further along, already reporting substantial net income, whereas CLOV is just reaching its first full-year of GAAP profitability. Sentiment has been favorable for both, but OSCR offers more established earnings visibility, while CLOV carries higher volatility and a more speculative profile.
Based on observable factors including trend consistency, earnings visibility, scale, and the cadence of positive guidance revisions, Tickeron's AI would currently lean toward OSCR as the relatively stronger choice between the two. Oscar Health's combination of demonstrated profitability, a more diversified state footprint, improving medical loss ratios, and repeated upward revisions to its outlook suggests a more stable and predictable earnings trajectory. Clover Health offers compelling growth and a genuine profitability inflection, but its smaller scale, geographic concentration, and higher volatility introduce comparatively more uncertainty. This assessment is probabilistic in nature and reflects current conditions rather than a definitive or guaranteed outcome. I’m watching this closely as conditions evolve.
In my analysis, I frequently review Tickeron’s AI Trading Bots to understand how automated strategies are positioning in names like these. The platform shows real-time performance data across hundreds of bots, helping identify which approaches align with current trends without relying on static models. This adds a useful layer when comparing opportunities such as CLOV and OSCR.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where CLOV declined for three days, in 281 of 330 cases, the price declined further within the following month. The odds of a continued downward trend are 85%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 42 of 56 cases where CLOV's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on CLOV as a result. In 64 of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for CLOV just turned positive on November 09, 2026. Looking at past instances where CLOV's MACD turned positive, the stock continued to rise in 38 of 47 cases over the following month. The odds of a continued upward trend are 81%.
CLOV moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLOV advanced for three days, in 225 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
CLOV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CLOV's P/B Ratio (6.804) is slightly higher than the industry average of (3.520). P/E Ratio (-120.500) is within average values for comparable stocks, (126.353). CLOV's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (0.786). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (0.970) is also within normal values, averaging (0.569).
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating fairly steady price growth. CLOV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 56 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLOV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry ManagedHealthCare